Cobenfy

Real talk about psychopharmacology, clinical confidence, and building a practice you love — from Lindsay and the Fellowship faculty.

Editorial still-life of a small ceramic anatomical brain sculpture with two softly glowing accent points suggesting two distinct receptor targets, a small unlabeled amber medicine bottle with a few capsules beside it, an upright fountain pen across a closed manila folder, and a ceramic mug of herbal tea with gentle steam on a quiet wooden desk in soft natural side light — header illustration for a 2026 PMHNP prescribing guide to Cobenfy (xanomeline-trospium), the first new-mechanism antipsychotic for schizophrenia in decades.

Clinical Practice

Cobenfy for Schizophrenia: A 2026 PMHNP Prescribing Guide

Cobenfy is the first schizophrenia drug that skips D2 blockade entirely. Here is how PMHNPs dose, titrate, and monitor xanomeline-trospium safely in 2026.

May 15, 2026 Read More →

Cobenfy

Cobenfy for Schizophrenia: A 2026 PMHNP Prescribing Guide

Join the Fellowship today.